This article was originally published in The Tan Sheet
"Underutilized" antiperspirant/deodorant line should get a boost from launch of new Mitchum Max extension, Revlon said during a Feb. 18 analyst meeting in New York City. Brand's gross sales in 2003 were $69 mil. while the line held a 7% to 8% market share, according to President & CEO Jack Stahl...
You may also be interested in...
Data show Opdivo/Cabometyx combo bests Sutent for overall and progression-free survival and response endpoints in first-line RCC. Exelixis CEO says comparison to Sutent is standard control and allows better comparison to other combo regimens.
ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.
In an update to stakeholders, the US FDA says regulators can successfully evaluate a firm’s performance, allowing it to eventually get medical software to market in the agency’s Pre-Cert Program.